Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-A randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events

American Heart Journal

Volumn 159, Issue 3, 2010, Pages

  Teramoto, Tamio ^a   Shimada, Kazuyuki ^b   Uchiyama, Shinichiro ^c   Sugawara, Masahiro ^d   Goto, Yoshio ^d   Yamada, Nobuhiro ^e   Oikawa, Shinichi ^f   Ando, Katsuyuki ^g   Ishizuka, Naoki ^h   Yamazaki, Tsutomu ⁱ   Yokoyama, Kenji ^j   Murata, Mitsuru ^j   Ikeda, Yasuo ^k  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d Japan Physician's Association   (Japan)

^e UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

^f NIPPON MEDICAL SCHOOL   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h Technical Research Institute   (Japan)

ⁱ GRADUATE SCHOOL OF MEDICINE   (Japan)

^j KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k WASEDA UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BAYASPIRIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; INSULIN; NATEGLINIDE; PROBUCOL; STATIN; SULFONYLUREA; UNCLASSIFIED DRUG;

ADULT; AGED; ANGINA PECTORIS; ARTERIOSCLEROSIS; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; INTERVENTION STUDY; ISCHEMIC HEART DISEASE; JAPANESE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; SURGICAL TECHNIQUE; TRANSFUSION; TRANSIENT ISCHEMIC ATTACK;

EID: 77749258073     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.11.030     Document Type: Article

References (33)

1. The Ministry of Health, Labour and Welfare, Japan. Ministry of Health, Labour and Welfare Report: 2007. [Japanese]. Available at:. http://www.mhlw.go.jp/wp/hakusyo/kousei/07/dl/0102-a.pdf Published 2007. Last accessed July 30, 2009
2. Antithrombotic Trialists', and Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
3. Ryan T.J., Antman E.M., Brooks N.H., et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 34 (1999) 890-911
4. Smith Jr. S.C., Blair S.N., Bonow R.O., et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for health care professionals from the American Heart Association and the American College of Cardiology. Circulation 104 (2001) 1577-1579
5. Albers G.W., Hart R.G., Lutsep H.L., et al. AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 30 (1999) 2502-2511
6. Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 19 (1998) 1434-1503
7. Royal College of Physicians. National clinical guidelines for stroke. 2nd ed. (2004), RCP, London Prepared by the Intercollegiate Stroke Working Party
8. The Joint Study Group 1998-1999. Guidelines for secondary prevention of myocardial infarction. Jpn Circ J 64 Suppl IV (2000) 1081-1127 [Japanese]
9. The Joint Study Group 2000-2001. Guidelines for management of acute coronary syndrome without persistent ST-segment elevation (JCS 2002). Circ J 66 Suppl VI (2002) 1123-1163 [Japanese]
10. Joint Committee on Guidelines for the Management of Stroke. Japanese guidelines for the management of stroke (2004) (2004), Kyowa Kikaku, Inc., Tokyo [Japanese]
11. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989) 129-135
12. Peto R., Gray R., Collins R., et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296 (1988) 313-316
13. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351 (1998) 233-241
14. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
15. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357 (2001) 89-95
16. Ridker P.M., Cook N.R., Lee I.M., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005) 1293-1304
17. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009) 1849-1860
18. Ogawa H., Nakayama M., Morimoto T., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008) 2134-2141
19. Yamazaki T., Goto S., Shigematsu H., et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan: results from domestic baseline data of the REduction of Atherothrombosis for Continued Health (REACH) Registry. Circ J 71 (2007) 995-1003
20. Bhatt D.L., Steg P.G., Ohman E.M., et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295 (2006) 180-189
21. World Health Organization. Mortality Database, 2007. Available at:. http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls Last accessed July 30, 2009
22. Hansson L., Hedner T., and Dahlof B. Prospective randomized blinded end-point (PROBE) Study: a novel design for intervention trials. Blood Press 1 (1992) 113-119
23. Committee on Guidelines for the Management of Hypertension in the Japanese Society of Hypertension. Guidelines for the management of hypertension (JSH 2004) (2004), The Japanese Society of Hypertension [Japanese]
24. Japan Atherosclerosis Society. Japan Atherosclerosis Society (JAS) guidelines for diagnosis and treatment of atherosclerotic cardiovascular diseases 2002 (2002), Japan Atherosclerosis Society [Japanese]
25. Japan Diabetes Society. Evidence-based practice guideline for the treatment of diabetes in Japan (2004), Nankodo Co Ltd, Tokyo [Japanese]
26. Luepker R.V., Apple F.S., Christenson R.H., et al. Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a Statement From the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 108 (2003) 2543-2549
27. Arai H., Yamamoto A., Matsuzawa Y., et al. Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb 13 (2006) 202-208
28. Morimoto T., Fukui T., Lee T.H., and Matsui K. Application of U.S. Guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan. Am J Med 117 (2004) 459-468
29. Ohkubo T., Obara T., Funahashi J., et al., and the J-HOME Study Group. Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: first report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) Study. Hypertens Res 27 (2004) 755-763
30. Teramoto T., Kashiwagi A., Mabuchi H., and for the J-LAP Investigators. Status of lipid-lowering therapy prescribed based on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults; a study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res Clin Exp 66 (2005) 80-95
31. Sone H., Kawai K., Takagi H., et al. Outcome of one-year of specialist care of patients with type 2 diabetes: a multi-center prospective survey (JDDM 2). Intern Med 45 (2006) 589-597
32. Yamamoto T., Sanaka M., Nagasawa K., et al. Gastroduodenal mucosal injury in patients on antiplatelet therapy. Thromb Res 120 (2007) 465-469 [Epub 2007 Jan 24]
33. Derry S., and Loke Y.K. Risk of gastrointestinal hemorrhage with long-term use of aspirin: meta-analysis. BMJ 321 (2000) 1183-1187